PEPCK-insulin gene construct and transgenic mouse
US6137029A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 3, 1996 |
| Grant date | Oct 24, 2000 |
| Priority date | — |
| Expiry date | Jun 3, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/027
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The chimeric gene is directed by a promoter or fusion of promoters which preferably are regulable and activated by the diabetic process. Preferably, it is obtained by fusion of the human insulin gene to the promoter of PEPCK (P-enolpiruvate carboxiquinasa). Said promoter (fragment -460 bp to +73 bp) is fused to the flank zone 5' of the human insulin gene (-170 bp to +1). The gene of the human insulin contains two coding exons E1 and E2 and two introns A and B. It also relates to an expression vector which allows the expression of insulin in cells which are different from the .beta.-cells of the pancreas, and to a transgenic mouse which expresses said chimeric gene.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.